Aim HER2 status is vital for selecting breast cancer patients for trastuzumab treatment. One recommended approach is to assess immunohistochemical staining and then perform in situ hybridisation on those tumours with a borderline (2+) immunohistochemical result. This audit aimed to assess the value of the percentage of immunohistochemical staining in 2+ tumours in selecting tumours for in-situ hybridisation.
Methods HER2 immunohistochemistry and in situ hybridisation was performed according to UK guidelines. The percentage of complete membrane staining of invasive carcinoma cells for HER2 was recorded as part of routine reporting.
Results 191 (11%) of 1735 invasive carcinomas were scored as 3+. 419 (24%) were scored as 2+. 57 of 413 2+ carcinomas (14%) were amplified (ratio of HER2 to chromosome 17≥2.0). The frequency of amplification was related to the percentage of complete membrane staining: eight of 149 (5%) with 10–19% membrane staining, 11 of 93 (12%) with 20–29% staining, 26 of 150 (17%) with 30–79% staining and 12 of 21 (57%) with 80–100% staining.
Conclusions This audit suggests that increasing the threshold for 2+ from 10% to 20% complete membrane staining would reduce the number of in-situ hybridisation tests by 36%, but reduce the detection of amplified tumours by 14%.
- Breast cancer
- breast carcinoma
- in-situ hybridisation
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests IOE and ZH work for Source BioScience. The other authors declare no conflicts of interest.
Provenance and peer review Not commissioned; externally peer reviewed.